Some of the biggest antibiotic drug development news this week was provided by a Lancet Infectious Diseases publication, with early results published from the phase two trial of cefiderocol compared with imipenem-cilastatin for the treatment of complicated gram-negative urinary pathogens. Cefiderocol was non-inferior to imipenem-cilastatin in the trial, and the study reports ongoing trials on other infection sites. The story was picked up by multiple media sites, and you can read the original article .
If you enjoyed this article and would like to build a career in global health, we offer a range of MSc programmes covering health and data, infectious and tropical diseases, population health, and public health and policy.
Available on campus or online, including flexible study that works around your work and home life, be part of a global community at the UK's no.1 public health university.